about
sameAs
Environmental and social benefits of the targeted intraoperative radiotherapy for breast cancer: data from UK TARGIT-A trial centres and two UK NHS hospitals offering TARGIT IORTTargeted intraoperative radiotherapy (TARGIT) yields very low recurrence rates when given as a boostTargeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trialLong-term results of targeted intraoperative radiotherapy (Targit) boost during breast-conserving surgery.Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial.Intraoperative radiotherapy for early breast cancer: do health professionals choose convenience or risk?Participating in an International Stereotactic Radiotherapy Patient Registry: The Establishment of Data Collection Pathways.Cosmesis and Breast-Related Quality of Life Outcomes After Intraoperative Radiation Therapy for Early Breast Cancer: A Substudy of the TARGIT-A Trial.Objective assessment of cosmetic outcome after targeted intraoperative radiotherapy in breast cancer: results from a randomised controlled trial.Effect of testosterone deprivation on the cognitive performance of a patient with Alzheimer's disease.Targeted intraoperative radiotherapy for breast cancer in patients in whom external beam radiation is not possible.Cosmetic outcome as rated by patients, doctors, nurses and BCCT.core software assessed over 5 years in a subset of patients in the TARGIT-A Trial.Intraoperative radiotherapy for breast cancerCirculating Tumour Cells (CTC), Head and Neck Cancer and Radiotherapy; Future PerspectivesIntraoperative radiotherapy: the debate continuesAdverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancerPatient preferences for adjuvant radiotherapy in early breast cancer are strongly influenced by treatment received through random assignment
P50
Q24658541-36930339-E1D4-40D2-9DEF-9A2FBAC9F5BFQ28272297-2C1D5B90-C926-4D52-B797-AB9CD3B026D2Q28285969-1796B137-A1D3-405A-A659-3A2BFCAEACECQ34144051-BFF2D91C-AFA1-41B7-91FD-B54CB119E9D3Q34384718-33DFBDFD-F34C-4114-969B-784D6EF48AF2Q37533221-63B9DD89-702F-4214-8FB1-79BB0B70C7D4Q38601333-48A132C7-AA52-4950-A2FD-C3428FC84C50Q39501751-8AF11248-4E36-493B-9C59-0F3CB99F9312Q40126092-E783A40A-7697-46E0-A291-DEA99E7E8870Q43728435-F99245E2-B8B7-464F-BE1D-908288416067Q45141808-21AEA82B-FEF5-41B9-9484-64DB0D9EF9A8Q55332440-E5760B4B-8FD1-4539-B9A1-A37D550D53FCQ61626894-8AF7467D-9636-4D03-80C0-E546512D24C0Q64086042-5F24D955-EB81-4E1D-AB19-9D1CCCEF8757Q80149859-8E4340DE-EA27-425F-A888-4F9F828EE3FFQ83189067-40324E8A-01FD-456A-ADD1-23238CCE581AQ91023195-72024EF7-9104-455C-8DC8-7185919013A6
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-1197-0120
@en
name
Tammy Corica
@ast
Tammy Corica
@en
Tammy Corica
@es
Tammy Corica
@nl
type
label
Tammy Corica
@ast
Tammy Corica
@en
Tammy Corica
@es
Tammy Corica
@nl
prefLabel
Tammy Corica
@ast
Tammy Corica
@en
Tammy Corica
@es
Tammy Corica
@nl
P106
P1153
6507561676
P31
P496
0000-0002-1197-0120